South Korea · Delayed Price · Currency is KRW HansBiomed Statistics
Total Valuation
HansBiomed has a market cap or net worth of KRW 362.24 billion. The enterprise value is 386.27 billion.
| Market Cap | 362.24B |
| Enterprise Value | 386.27B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HansBiomed has 14.26 million shares outstanding. The number of shares has increased by 1.84% in one year.
| Current Share Class | 14.26M |
| Shares Outstanding | 14.26M |
| Shares Change (YoY) | +1.84% |
| Shares Change (QoQ) | +6.79% |
| Owned by Insiders (%) | 24.56% |
| Owned by Institutions (%) | 12.36% |
| Float | 9.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 17.31 |
| PS Ratio | 3.28 |
| PB Ratio | 4.90 |
| P/TBV Ratio | 4.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.57.
| Current Ratio | 1.24 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.86 |
| Interest Coverage | -12.45 |
Financial Efficiency
Return on equity (ROE) is -36.94% and return on invested capital (ROIC) is -22.82%.
| Return on Equity (ROE) | -36.94% |
| Return on Assets (ROA) | -10.13% |
| Return on Invested Capital (ROIC) | -22.82% |
| Return on Capital Employed (ROCE) | -26.27% |
| Weighted Average Cost of Capital (WACC) | 13.32% |
| Revenue Per Employee | 372.05M |
| Profits Per Employee | -83.66M |
| Employee Count | 297 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 1.56 |
Taxes
In the past 12 months, HansBiomed has paid 2.31 billion in taxes.
| Income Tax | 2.31B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +155.71% in the last 52 weeks. The beta is 1.86, so HansBiomed's price volatility has been higher than the market average.
| Beta (5Y) | 1.86 |
| 52-Week Price Change | +155.71% |
| 50-Day Moving Average | 29,735.00 |
| 200-Day Moving Average | 28,977.50 |
| Relative Strength Index (RSI) | 44.55 |
| Average Volume (20 Days) | 327,615 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HansBiomed had revenue of KRW 110.50 billion and -24.85 billion in losses. Loss per share was -1,867.30.
| Revenue | 110.50B |
| Gross Profit | 65.37B |
| Operating Income | -22.41B |
| Pretax Income | -23.39B |
| Net Income | -24.85B |
| EBITDA | -17.67B |
| EBIT | -22.41B |
| Loss Per Share | -1,867.30 |
Balance Sheet
The company has 17.95 billion in cash and 42.23 billion in debt, with a net cash position of -24.27 billion or -1,701.97 per share.
| Cash & Cash Equivalents | 17.95B |
| Total Debt | 42.23B |
| Net Cash | -24.27B |
| Net Cash Per Share | -1,701.97 |
| Equity (Book Value) | 73.98B |
| Book Value Per Share | 5,204.87 |
| Working Capital | 15.14B |
Cash Flow
In the last 12 months, operating cash flow was -20.21 billion and capital expenditures -2.45 billion, giving a free cash flow of -22.66 billion.
| Operating Cash Flow | -20.21B |
| Capital Expenditures | -2.45B |
| Depreciation & Amortization | 4.74B |
| Net Borrowing | -2.01B |
| Free Cash Flow | -22.66B |
| FCF Per Share | -1,588.89 |
Margins
Gross margin is 59.16%, with operating and profit margins of -20.28% and -22.49%.
| Gross Margin | 59.16% |
| Operating Margin | -20.28% |
| Pretax Margin | -21.17% |
| Profit Margin | -22.49% |
| EBITDA Margin | -15.99% |
| EBIT Margin | -20.28% |
| FCF Margin | n/a |
Dividends & Yields
HansBiomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.84% |
| Shareholder Yield | -1.84% |
| Earnings Yield | -6.86% |
| FCF Yield | -6.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HansBiomed has an Altman Z-Score of 2.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.28 |
| Piotroski F-Score | 3 |